ArticleCurrent oncology (Toronto, Ont.)2024

Trends in Real-World Clinical Outcomes of Patients with Anaplastic Lymphoma Kinase (ALK) Rearranged Non-Small Cell Lung Cancer (NSCLC) Receiving One or More ALK Tyrosine Kinase Inhibitors (TKIs): A Cohort Study in Ontario, Canada.

Lara Chayab et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.